Shanghai - 18 September 2012 - GlaxoSmithKline (China) R&D Co., Ltd. recently has signed a deal with OceanX to use OceanFax FoIP to effectively transition from traditional to paperless faxing, replacing fax machine.

 

Highlights

OceanFax FoIP with VM solution The global pioneering and Asia’s first boardless network fax solution Leverage investment in existing IP telephony infrastructure No need for additional hardware for faxing Delegate groups to view and forward public account’s inbound faxes for public sharing Email integration 2 channels

 

About OceanFax FoIP

OceanFax FoIP is the global pioneering and Asia’s first boardless (software only) Fax over IP solution. Leveraging your investment in planned or existing IP telephony infrastructure, OceanFax FoIP supports real time fax transmission over the internet on a VoIP network, with the most advanced FoIP integration for Cisco, Avaya, Alcatel-Lucent, Microsoft Lync, Siemen, Dialogic, Shoretel IPT and AudioCodes Fax/Voice gateways. OceanFax FoIP software is typically deployed and administered in virtual machine (VM) environment using VMware, Hyper-V and Virtual PC, instead of a physical server, with no need for additional hardware for faxing. As a mature, field-proven boardless FoIP solution, OceanFax FoIP is innovative, fast, secure and robust that has proven its market leadership in the FoIP industry, managing large fax volumes and delivers high levels of scalability, reliability and availability. By applying it, organizations drastically reduce telecom costs, protect document privacy more effectively and facilitate compliance with regulations, as well as seamlessly integrate Fax into Email, ERP and MFP. For more information, please visit OceanFax FoIP.

 

About Glaxosmithkline

GlaxoSmithKline plc (GSK) (LSE: GSK, NYSE: GSK) is a British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is the world's fourth-largest pharmaceutical company measured by 2009 prescription drug sales. It was established in 2000 by the merger of Glaxo Wellcome plc and SmithKline Beecham plc. GSK has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes, and digestive conditions.
GSK opened its first R&D centre in China in May 2007, located in Shanghai and initially focused on neurodegenerative diseases.

 

Previous piece of news